OncoMatch/Clinical Trials/NCT06088654
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Is NCT06088654 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies IPH6501 for non hodgkin lymphoma.
Treatment: IPH6501 — This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (CD20+)
CD20+ B-cell non-Hodgkin's lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody therapy (rituximab)
at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy
Cannot have received: chemotherapy
Exception: within less than 4 weeks before study drug administration
Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration.
Cannot have received: immunotherapy
Exception: within less than 4 weeks before study drug administration
Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration.
Cannot have received: anti-cancer therapy
Exception: within less than 4 weeks before study drug administration
Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration.
Cannot have received: autologous stem cell transplant
Exception: within 100 days prior to first dose of study drug
Autologous stem cell transplant ... within 100 days prior to first dose of study drug
Cannot have received: CAR-T cell therapy
Exception: within 100 days prior to first dose of study drug
treatment with CAR-T (Chimeric Antigen Receptor T-Cell) cell therapy within 100 days prior to first dose of study drug
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and hematological function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Cedars Sinai · Los Angeles, California
- Siteman Cancer Center · St Louis, Missouri
- Icahn School Of Medicine At Mount Sinai · New York, New York
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify